The first implantations of Samsara Vision’s SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) have been performed on patients with late-stage, age-related macular degeneration (AMD) as part of the CONCERTO US Food and Drug Administration (FDA) study to evaluate improvements in visual acuity and safety of the device.
Samsara Vision describes SING IMT as a Galilean-style telescope implant designed to improve visual acuity and quality of life for patients with late-stage AMD. Its pre-loaded delivery system allows insertion during typical outpatient cataract surgery with a corneal incision range of 6.5-7.5 mm. Images seen in ‘straight-ahead’ vision are magnified 2.7 times and projected onto healthy, undamaged areas of the macula, reducing the apparent impact of the blind spot on central vision.
The trial’s 100 adults aged 65-plus with stable (non-active neovascularisation), bilateral central scotomas (blind spots) due to late-stage AMD will receive a SING IMT in one eye, followed by visual rehabilitation.
